What's Happening?
Biogen and Eisai's Alzheimer's treatment, Leqembi, is showing signs of commercial success in the U.S. market. In the fourth quarter, global sales of Leqembi, an anti-amyloid antibody, increased by 54% to $134 million, with $78 million coming from the U.S. This growth partially offset declines in Biogen's multiple sclerosis franchise. The FDA recently approved a subcutaneous injection version of Leqembi, which can be used during the maintenance phase of treatment, reducing the need for infusion clinic visits. Currently, patients must receive the drug via IV infusion for the first 18 months. Biogen and Eisai are seeking FDA approval to use the injectable version as a starting treatment, with a decision expected in early May.
Why It's Important?
The commercial success
of Leqembi is significant for Biogen and Eisai as it helps offset declines in other areas, such as multiple sclerosis and spinal muscular atrophy treatments. The approval of a more convenient subcutaneous version could further boost sales and patient accessibility. This development is crucial for Biogen, which is focusing on strong execution and financial discipline amid a challenging market environment. The success of Leqembi and other growth products like Skyclarys and Zurzuvae is vital for Biogen's financial health and strategic positioning in the biopharmaceutical industry.
What's Next?
Biogen and Eisai are awaiting an FDA decision on expanding the use of the injectable version of Leqembi, which could further increase its market uptake. Additionally, Biogen is anticipating results from phase 3 trials of litifilimab, an anti-BDCA2 antibody for lupus, which could have significant sales potential. These developments are part of Biogen's strategy to strengthen its product portfolio and drive future growth.
